Brought to you by 
Epigenomics grants GSTP1 rights to Predictive Biosciences
31 Jan 2011
Executive Summary
Exercising an option it received in April 2009, Predictive Biosciences Inc. has licensed nonexclusive rights to develop and sell in the US a prostate cancer test based on fellow molecular diagnostics firm Epigenomics AG's proprietary DNA methylation biomarker GSTP1.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Urine-based Testing
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Epigenomics grants GSTP1 rights to Predictive Biosciences
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice